Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects
BACKGROUND: Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised. The mechanisms of action and predisposing factors have not yet been fully understood.METHOD:...
Saved in:
Published in | The international journal of tuberculosis and lung disease Vol. 12; no. 8; pp. 967 - 971 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Paris, France
IUATLD
01.08.2008
Union internationale contre la tuberculose et les maladies respiratoires |
Subjects | |
Online Access | Get full text |
ISSN | 1027-3719 |
Cover
Summary: | BACKGROUND: Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised. The mechanisms of action and predisposing factors have not yet been fully understood.METHOD:
We conducted a retrospective study (1992-2007) in an attempt to find predisposing factors for optical neuropathy.RESULTS: Visual disturbance was reported in 1.3% of the 760 patients treated with EMB; of these, 0.8% were EMB-related. We present the six cases; four were clearly overdosed,
but in two obese patients dosage was correctly calculated for total body weight (TBW).CONCLUSION: Analysis of the case histories and previous reports suggest that optical neuropathy may at least partly be caused by EMB overdosing due to daily dosing based on TBW instead of dosing on lean
body mass. |
---|---|
Bibliography: | (R) Medicine - General 1027-3719(20080801)12:8L.967;1- ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Case Study-2 ObjectType-Feature-4 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 1027-3719 |